Baruch S. Blumberg Institute

Baruch S. Blumberg Institute, a tax-exempt non-profit biomedical research organization based in Doylestown, Pennsylvania, functions as a prime recipient of federal grants and research contracts focused on infectious disease and cancer therapeutics, with no competitive bidding posture and no seat on federal contract vehicles. The institute is a child entity of the Hepatitis B Foundation and operates entirely through federal grant funding and fixed-fee research contracts rather than through competitive procurement.

The institute's recent federal footprint centers on virology, gene therapy, and diagnostic development. Its flagship award is a $32.3 million cost-plus-fixed-fee definitive contract from the National Institute of Allergy and Infectious Diseases (NIAID) issued November 15, 2022, to develop an orally available small-molecule antiviral for yellow fever virus infection, with performance through November 2027 and Utah State University named as a subcontractor. Recent grant work includes a NIAID-funded R21 project grant awarded February 10, 2026 (running through January 2028) to develop and validate a novel RNA sensing and editing-dependent hepatitis B virus infection reporter system for unbiased genetic screening; a NIAID R21/R33 project grant awarded January 2024 (through December 2026) to advance chemically ligated guide RNA-based CRISPR/Cas9 gene editing for hepatitis B cure; and a NIAID project grant awarded September 2023 to develop liver-targeted dihydroquinolizinone molecules as hepatitis B antivirals with reduced toxicity. The Defense Health Agency has funded two military medical research grants: a $1.191 million project grant awarded August 2024 investigating novel mechanisms governing human breast cancer chromosomal instability (through July 2027) and a $160 thousand project grant awarded September 2023 on enhancing natural killer cell cytotoxicity toward cholangiocarcinoma (completed August 2024). The National Cancer Institute funded a cooperative agreement in February 2023 (running through January 2028) for research on hepatocellular carcinoma DNA detection in urine, for which the institute acts as sub-recipient under the General Hospital Corporation as prime grantee.

Customer concentration is pronounced. NIAID dominates with ten awards totaling $32.3 million combined potential value, representing all of the institute's contract work and the majority of its grant portfolio. The Defense Health Agency and National Cancer Institute each fund multiple grants. Five awards (combined potential value $32.3 million) reach ultimate completion within the next twenty-four months, concentrating recompete exposure in the NIAID yellow fever antiviral contract and related grant work. The institute's sub-recipient footprint includes work under the General Hospital Corporation on hepatitis B liquid biopsy development, under the Medical University of South Carolina on academic entrepreneur technology launch support, and under Genelancet Biosciences on supplementary research aims. Total federal awards across all sources number 29 (25 as prime, 4 as sub), with combined potential value of $33.9 million against $54.1 million obligated, reflecting multi-year grant commitments and contract modifications. Activity is sparse and irregular — one award in 2021, two in 2022, four in 2023, two in 2024, and three in 2026 — and the institute competes in the non-competitive federal research grant space rather than in contract procurement.